High-dose thiotepa has been successfully included in a variety of conditioning regimens for stem cell transplantation in hematological and solid neoplasms. Toxicity of high-dose thiotepa mainly manifests as profound myeloablation and some degree of liver damage. We report a case of inappropriate secretion of antidiuretic hormone (SIADH) in a patient with primary CNS lymphoma who underwent therapy with high-dose thiotepa. Keywords: thiotepa; SIADH; autologous stem cell transplantation Thiotepa is a well-known antineoplastic agent with high efficacy against solid tumors and hematological malignancies. Its pharmacological profile is particularly favourable and it has been included in a variety of pre-transplantation conditioning regimens. Thiotepa also shows excellent central nervous system penetration and its efficacy has been proven in the treatment of cerebral neoplasms.
Thiotepa is a well-known antineoplastic agent with high efficacy against solid tumors and hematological malignancies. Its pharmacological profile is particularly favourable and it has been included in a variety of pre-transplantation conditioning regimens. Thiotepa also shows excellent central nervous system penetration and its efficacy has been proven in the treatment of cerebral neoplasms. 1 There are few reports of serious central nervous system toxicity of thiotepa, these being limited to tremors and dizziness. We describe the first report of inappropriate secretion of antidiuretic hormone syndrome (SIADH) after high-dose thiotepa.
Case report
A 41-year-old female affected by primary central nervous system lymphoma (PCNSL) was referred for autologous peripheral blood stem cell transplant in second complete remission. The patient had been previously treated with systemic and intrathecal chemotherapy, and involved field radiation therapy. At the time of admission she was in good clinical condition and neurological examination was normal. Conditioning therapy included thiotepa 250 mg/m 2 day −9 to day −7, busulfan 1 mg/kg every 6 h for 10 doses and cyclophosphamide 60 mg/kg day −3 and day −2. trose 1000 ml/m 2 was started on day −9. Dyphenylhydantoin at a loading dose of 1 g p.o. followed by 200 mg/m 2 was prophylactically administered from day −9 to prevent busulfan-induced seizures. On day −6, 12 h after the last dose of thiotepa and a few hours after the first dose of busulfan she developed severe headache and vomiting followed by seizures. There was no clinical evidence of fluid depletion as documented by normal blood pressure and serial weight measurement. NMR revealed the absence of active disease or signs of elevated intracranial pressure. The serum sodium concentration at this time fell from 134 (day −5) to 119 mEq/l (day −6 early morning blood sample) (Figure 1 ). Serum osmolality was 246 mOsm/kg H 2 O, and urinary osmolality 450 mOsm/kg H 2 O (Osmostat OM-6020, Kagaku, Kyoto, Japan). Urinary sodium concentration was 160 mEq/l. Administration of normal saline, diuretics and fluid restriction was followed by a rapid normalization of the hyponatremia ( Figure 1 ) together with normalization of the neurological condition. The patient recovered completely and is alive and well 6 months after autologous stem cell transplantation.
Discussion
The findings of hyponatremia with corresponding serum hypo-osmolality and continuing urinary sodium excretion are compatible with a diagnosis of SIADH in the presence of normovolemia. In this case high-dose thiotepa was felt to be the cause of the SIADH since it was the only chemotherapeutic agent administered before the onset of the syndrome. Hyponatremia, in fact, developed prior to busulfan administration. The absence of hypovolemia was not consistent with water and salt loss. Moreover, the patient required fluid restriction. Profound damage of the bloodbrain barrier determined by the disease itself or by previous exposure to systemic and intrathecal chemotherapy, and/or radiotherapy may have contributed to the development of SIADH. The absence of active CNS lymphoma, a recognized cause of SIADH, in this patient excludes its causal role in the SIADH. The role of dyphenylhydantoin as a potential inhibitor of ADH secretion was not felt to be relevant here. Fluid balance and electrolyte assessment are of paramount importance in the diagnosis of SIADH and in its management which include fluid restriction, diuretics and saline infusions. Patients undergoing high-dose chemotherapy are exposed to a variety of antineoplastic and nonantineoplastic drugs that could interfere with ADH secretion, and CNS involvement and/or the disruption of blood-brain barrier may favor SIADH development. Thiotepa has not been reported previously to be a cause of SIADH although Kleta et al 3 recently reported a case of SIADH in a patient exposed to a high-dose regimen including thiotepa, carboplatin and etoposide phosphate. In that particular report, the authors felt that etoposide phosphate was the causative agent. Strict monitoring of fluid balance and electrolytes should be undertaken during conditioning therapy in order to detect the onset of SIADH promptly and allow immediate treatment.
